GlassScriptPhysician profile
Susan Keiler
NPI 1063602811
$44,185.34
in general payments reported to CMS, 2019-2025
38 companies · $4,793 in 2025
The $4,793 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $7,904 · 2021: $2,931 · 2022: $2,536 · 2023: $4,035 · 2024: $3,839 · 2025: $4,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,238.42 |
| Education | $428.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $15,524.15 | 2019 | |
| Amgen INC. | $6,716.84 | 2019-2025 | Otezla, Otezla |
| Abbvie INC. | $3,732.34 | 2019-2025 | |
| Ucb, INC. | $2,030.29 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $1,769.30 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $1,742.07 | 2019-2025 | |
| Pfizer INC. | $1,598.57 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,485.90 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Lilly USA, LLC | $1,436.37 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $1,328.62 | 2019-2025 | |
| Janssen Biotech, INC. | $1,299.36 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Incyte Corporation | $878.56 | 2021-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $743.11 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $698.45 | 2022-2024 | Vtama |
| Leo Pharma INC. | $534.17 | 2019-2025 | Adbry, Anzupgo |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Keiler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.